ProfileGDS5678 / 1445872_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 29% 29% 27% 29% 32% 28% 29% 29% 29% 29% 30% 29% 29% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6992629
GSM967853U87-EV human glioblastoma xenograft - Control 22.6646629
GSM967854U87-EV human glioblastoma xenograft - Control 32.6695129
GSM967855U87-EV human glioblastoma xenograft - Control 42.579227
GSM967856U87-EV human glioblastoma xenograft - Control 52.6060729
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7942832
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6890328
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6434929
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.630129
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6546729
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6511529
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.65430
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6671229
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6626929